Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Oct 25, 2023
Trader Robot Strikes Again with +5.44% Weekly Gain on $ACET

Trader Robot Strikes Again with +5.44% Weekly Gain on $ACET

In the world of AI trading robots, the "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" has become a popular choice for investors. These sophisticated bots have been making waves in the financial market, recently delivering impressive results. During the previous week, these trading bots managed to secure a remarkable gain of +5.44% while actively trading ACET. In this article, we will delve into the specifics of ACET's earnings and market trends, shedding light on what's driving the success of these AI trading robots.

MACD Indicator: A Positive Omen for ACET

One of the key factors contributing to the success of the AI trading bots is the analysis of the Moving Average Convergence Divergence (MACD) indicator for ACET. On October 5, 2023, the MACD Histogram for ACET crossed above the signal line, signaling a positive trend. This is a significant technical indicator that often piques the interest of traders.

Historical data shows that when ACET's MACD turns positive, the stock tends to continue its upward trajectory. Out of 39 instances where the MACD turned positive, ACET's stock price rose in 34 of them over the following month. This historical data indicates an impressive 87% success rate for predicting an upward trend in ACET's stock price.

Earnings Report: A Mixed Bag for ACET

One critical aspect that AI trading bots consider when making trading decisions is the company's earnings. ACET reported its last earnings on August 09, which showed earnings per share (EPS) of -75 cents. This result fell short of the estimated -46 cents, highlighting a significant earnings miss.

To put this in perspective, with 153.57K shares outstanding, the current market capitalization for ACET stands at 64.60M. This earnings report will undoubtedly have an impact on the trading strategies employed by AI bots.

Dividend Dates and Their Implications

Investors often consider dividends when making trading decisions. ACET paid a quarterly dividend of $0.01 per share, with a record date of October 09, 2018, and an ex-dividend date of September 21, 2018. The ex-dividend date is an important factor to consider. If you buy a stock on or after this date, you won't receive the next dividend payment. Instead, the dividends are retained by the seller. However, if you purchase the stock before the ex-dividend date, you will receive the dividends.

Market Capitalization Insights

Understanding a company's market capitalization is crucial for investors. In the biotechnology industry, ACET's market capitalization of 64.60M places it on the lower end of the spectrum. The average market capitalization for companies in this industry is 2.19B, with a wide range of values, from 402M to 429.71B. For comparison, the highest-valued company in this group is NVO at 429.71B, while the lowest is PNEXF at 402M.

Price Trends and Volatility in the Biotechnology Industry

Market trends play a significant role in the success of AI trading bots. In the biotechnology industry, the average weekly price growth for all stocks was -3%, indicating a slight decline. The average monthly price growth was -5%, while the average quarterly price growth was -15%. These figures suggest a challenging environment for traders in this industry.

Notably, ADXN experienced the highest price growth at a staggering 1,510%, showcasing the potential for significant gains in the biotech sector. Conversely, ATHX experienced a substantial decline, with a -82% drop in its stock price, highlighting the industry's inherent volatility.

Volume: An Indicator of Trading Activity

Trading volume is a crucial indicator for traders and AI trading bots. In the biotechnology industry, the average weekly volume growth for all stocks was -25%, suggesting a decline in trading activity. On a monthly basis, the average volume growth was -6%, indicating a persistent downtrend. However, the quarterly volume growth was a notable exception, showing a significant 72% increase in trading activity.

In summary, the success of AI trading robots is often attributed to their ability to analyze a plethora of data, including technical indicators, earnings reports, market trends, and trading volumes. The positive MACD crossover for ACET, despite a recent earnings miss, suggests a potential upward trend. However, the broader trends in the biotechnology industry and trading volumes indicate a more challenging environment.

Related Ticker: ACET

Contributor

Dem Sem's AvatarDem Sem|Expert

ACET sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ACET moved above the 200-day moving average on August 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where ACET's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for ACET crossed bullishly above the 50-day moving average on July 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 178 cases where ACET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACET as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ACET turned negative on August 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

ACET moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ACET broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.646) is normal, around the industry mean (20.121). P/E Ratio (0.000) is within average values for comparable stocks, (25.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.855). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (466.660).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.25B. The market cap for tickers in the group ranges from 58 to 130.9B. VRTX holds the highest valuation in this group at 130.9B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 3,041%. ABCL experienced the highest price growth at 68%, while JUNS experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 38%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 57
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
ACET
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a distributor of pharmaceutical intermediate ingrediants and other industrial chemicals

Industry Biotechnology

Profile
Details
Industry
Medical Distributors
Address
131 Dartmouth Street
Phone
+1 650 503-9095
Employees
102
Web
https://www.adicetbio.com
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.